6-K filed Sep 14, 2026 at 07:24 ET
GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvutatug rezetecan) in relapsed small cell lung cancer in China. Ris-Rez reduced the risk of death by 54% vs topotecan (HR 0.46, p<0.0001), with median OS of 18.5 months vs 10.3 months, and showed a favorable safety profile. This is the first Phase III data to demonstrate an OS benefit for a B7-H3 ADC in any tumor type, supporting GSK's global development program with pivotal data from the EMBOLD SCLC-301 trial expected next year.